HVTN 108


Trial Details:

I/II Ongoing
National Institute of Allergy and Infectious Diseases (NIAID)
DNA-HIV-PT123,Bivalent Subtype C gp120/AS01B ,Bivalent Subtype C gp120/MF59
?Healthy adults
DNA clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef; Protein Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env
DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6 at varying concentrations.   ?